Cystatin C predicts cognitive decline in multiple system atrophy: A 1-year prospective cohort study

Zhang, Lingyu and Li, Ruicen and Hou, Yanbing and Cao, Bei and Wei, Qianqian and Ou, Ruwei and Liu, Kuncheng and Lin, Junyu and Yang, Tianmi and Xiao, Yi and Huang, Wenxia and Shang, Huifang (2022) Cystatin C predicts cognitive decline in multiple system atrophy: A 1-year prospective cohort study. Frontiers in Aging Neuroscience, 14. ISSN 1663-4365

[thumbnail of pubmed-zip/versions/1/package-entries/fnagi-14-1069837/fnagi-14-1069837.pdf] Text
pubmed-zip/versions/1/package-entries/fnagi-14-1069837/fnagi-14-1069837.pdf - Published Version

Download (868kB)

Abstract

Background: Accumulating evidence has suggested that cystatin C is associated with cognitive impairment in patients with neurodegenerative diseases. However, the association between cystatin C and cognitive decline in patients with multiple system atrophy (MSA) remains largely unknown.

Objectives: The objective was to determine whether cystatin C was independently associated with cognitive decline in patients with early-stage MSA.

Methods: Patients with MSA underwent evaluation at baseline and the 1-year follow-up. Cognitive function was evaluated with Montreal cognitive assessment (MoCA). Changes in the MoCA score and the absolute MoCA score at the 1-year assessment were considered the main cognitive outcome. The cystatin C concentrations in patients with MSA and age, sex, and body mass index matched-healthy controls (HCs) were measured. A multiple linear regression model was used to test the association between cystatin C and cognitive decline.

Results: A total of 117 patients with MSA and 416 HCs were enrolled in the study. The cystatin C levels were significantly higher in patients with MSA than in HCs (p < 0.001). Cystatin C levels were negatively correlated with MoCA score at baseline and at 1-year follow-up. Multiple linear regression model adjusted for potential confounders showed that baseline cystatin C levels were significantly associated with the MoCA score (p = 0.004) or change in the MoCA score (p = 0.008) at 1-year follow-up.

Conclusion: Our results suggested that cystatin C may serve as a potential biomarker of cognitive decline in patients with early-stage MSA.

Item Type: Article
Subjects: East Asian Archive > Medical Science
Depositing User: Unnamed user with email support@eastasianarchive.com
Date Deposited: 19 Jun 2024 12:31
Last Modified: 19 Jun 2024 12:31
URI: http://library.eprintdigipress.com/id/eprint/1315

Actions (login required)

View Item
View Item